Phase 1Completed
Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)
Open Label, Randomized, Single Dose, Two-way Crossover Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)
- Sponsor
- Genuine Research Center, Egypt (Industry)
- Enrollment
- 24 enrolled
- Conditions
- Healthy
- Interventions
- Vildagliptin; Vildagliptin
- Ages
- adults
- Registry
- NCT02816970
Full record on ClinicalTrials.gov
From the registry
An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Vildagliptin from Gliptus 50 mg tablet (EVA pharma, Egypt) and Galvus 50 mg tablet (NOVARTIS PHARMA, GERMANY) in Healthy Human Volunteers Under Fasting Condition
Primary outcomes
- Maximal measured plasma concentration (Cmax)
History
Registered
Study completion
Started
Primary completion